Elk Creek feasibility update posts $4.1B NPV but financing risk persists

What happened

NioCorp released an updated technical report for the Elk Creek Critical Minerals Project showing a $4.1 billion NPV and a 40-year mine life, reflecting an expanded product suite and updated mine design. The company remains pre-revenue and faces an estimated $1.141 billion upfront capex, with only $306 million in cash and no committed debt financing beyond the expired Yorkville facility. The new study may improve project economics on paper, but it does not address the two critical de-risking events: replacement of the equity facility and conversion of non-binding offtakes. Portal construction is underway, but actual costs could exceed the $44.6 million estimate, and dilution risk remains high if financing is not secured. Thus, the study is a positive technical milestone but not a substitute for committed capital.

Implication

Investors should treat the updated feasibility study as a planning document whose key assumptions (commodity prices, discount rate, capex) require independent validation, not as a basis for immediate revaluation. The study could improve EXIM diligence and lender confidence, but it does not guarantee a debt commitment, and the company still lacks a replacement for the expired Yorkville facility. Watch for announcements on definitive offtake agreements and any firm financing commitments rather than study metrics. Dilution risk remains acute because the company may be forced to raise equity at a discount to fund portal construction and pre-development costs. A sustained move above $8.50 without financing progress would likely be speculative, while a retreat toward $5.00 may offer a better risk/reward if the study's economics are credible.

Thesis delta

The updated feasibility study modestly strengthens the project's economic case, but the core thesis is unchanged: NB needs committed, non-dilutive financing and definitive offtakes to unlock value. The study may improve the odds of EXIM approval, yet it does not alter the immediate risk of equity dilution or the need for observable capital-stack progress. We maintain WAIT with no change to conviction or price targets pending evidence that the improved economics translate into financial commitments.